Conversely, lower expression levels of AHNAK2 were observed in glioblastoma multiforme, glioma (GBMLGG), brain lower grade glioma, breast invasive carcinoma, and prostate adenocarcinoma (Fig. 5A). This evidence concerns the gene AHNAK2 and invasive breast carcinoma.